SCHEMBL5356501

SCHEMBL5356501

O=c1[nH]nc2c(NCCNc3nc4ccccc4s3)nc3ccc(F)cc3n12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.52
BRD4 O60885 5/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ILK Q13418 1/20 0.37
GLS O94925 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NFKB1 P19838 1/20 0.37
HTT P42858 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5355187 0.89 ADORA1 (0.52) ADORA1BRD4NPC1RAB9ASMN1; SMN2
SCHEMBL5368059 0.89 ADORA1 (0.52) ADORA1NPC1RAB9AILKGLS
SCHEMBL5356547 0.81 ADORA1 (0.54) ADORA1BRD4NPC1RAB9ASMN1; SMN2
SCHEMBL5359692 0.81 ADORA1 (0.55) ADORA1NPC1RAB9APOLBSMN1; SMN2
SCHEMBL5361972 0.81 ADORA1 (0.53) ADORA1BRD4
SCHEMBL5357433 0.81 ADORA1 (0.53) ADORA1BRD4
SCHEMBL5362434 0.81 ADORA1 (0.77) ADORA1BRD4NPC1RAB9ASMN1; SMN2
SCHEMBL5355423 0.80 ADORA1 (0.53) ADORA1BRD4NPC1RAB9ASMN1; SMN2
SCHEMBL5357503 0.80 ADORA1 (0.54) ADORA1BRD4
SCHEMBL5362701 0.79 ADORA1 (0.75) ADORA1BRD4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202245-B2 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. (US) 2007-04-10 US claimed
EP-1613629-A1 SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES Pfizer Products Inc. (US) 2006-01-11 EP claimed
WO-2004085439-A1 SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES PFIZER PRODUCTS INC. (US) 2004-10-07 WO claimed
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. 2004-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines CYP4B1, CYP3A4, CYP1B1 ADORA1 12/4885BRD4 784/4885NPC1 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.